Jayson Bedford
Stock Analyst at Raymond James
(3.96)
# 648
Out of 4,732 analysts
297
Total ratings
56.43%
Success rate
8.32%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MMSI Merit Medical Systems | Maintains: Outperform | $105 → $110 | $102.90 | +6.90% | 26 | Dec 31, 2024 | |
| MASI Masimo | Maintains: Outperform | $170 → $194 | $172.29 | +12.60% | 6 | Dec 27, 2024 | |
| DXCM DexCom | Maintains: Strong Buy | $115 → $99 | $84.38 | +17.33% | 30 | Oct 25, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $128 → $123 | $109.56 | +12.27% | 6 | Oct 14, 2024 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $500 → $540 | $592.64 | -8.88% | 7 | Oct 14, 2024 | |
| PODD Insulet | Maintains: Outperform | $213 → $260 | $275.81 | -5.73% | 25 | Oct 14, 2024 | |
| ABT Abbott Laboratories | Maintains: Outperform | $122 → $129 | $113.48 | +13.68% | 27 | Oct 14, 2024 | |
| ICUI ICU Medical | Maintains: Outperform | $158 → $190 | $163.87 | +15.95% | 19 | Sep 12, 2024 | |
| BSX Boston Scientific | Maintains: Strong Buy | $91 → $94 | $98.66 | -4.72% | 22 | Sep 4, 2024 | |
| BDX Becton, Dickinson and Company | Maintains: Outperform | $275 → $270 | $237.38 | +13.74% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $18.09 | -28.14% | 1 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $12.43 | -19.55% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $172 → $175 | $147.03 | +19.02% | 20 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $181.27 | +49.50% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.23 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $35.15 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $69.78 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $30.98 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $88.08 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $0.85 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $69.73 | +23.33% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.14 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $24.10 | - | 3 | Jan 2, 2018 |
Merit Medical Systems
Dec 31, 2024
Maintains: Outperform
Price Target: $105 → $110
Current: $102.90
Upside: +6.90%
Masimo
Dec 27, 2024
Maintains: Outperform
Price Target: $170 → $194
Current: $172.29
Upside: +12.60%
DexCom
Oct 25, 2024
Maintains: Strong Buy
Price Target: $115 → $99
Current: $84.38
Upside: +17.33%
Zimmer Biomet Holdings
Oct 14, 2024
Maintains: Outperform
Price Target: $128 → $123
Current: $109.56
Upside: +12.27%
Intuitive Surgical
Oct 14, 2024
Maintains: Outperform
Price Target: $500 → $540
Current: $592.64
Upside: -8.88%
Insulet
Oct 14, 2024
Maintains: Outperform
Price Target: $213 → $260
Current: $275.81
Upside: -5.73%
Abbott Laboratories
Oct 14, 2024
Maintains: Outperform
Price Target: $122 → $129
Current: $113.48
Upside: +13.68%
ICU Medical
Sep 12, 2024
Maintains: Outperform
Price Target: $158 → $190
Current: $163.87
Upside: +15.95%
Boston Scientific
Sep 4, 2024
Maintains: Strong Buy
Price Target: $91 → $94
Current: $98.66
Upside: -4.72%
Becton, Dickinson and Company
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $237.38
Upside: +13.74%
Jul 1, 2024
Initiates: Outperform
Price Target: $13
Current: $18.09
Upside: -28.14%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $12.43
Upside: -19.55%
Jan 3, 2024
Maintains: Outperform
Price Target: $172 → $175
Current: $147.03
Upside: +19.02%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $181.27
Upside: +49.50%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.23
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $35.15
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $69.78
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $30.98
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $88.08
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.85
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $69.73
Upside: +23.33%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.14
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $24.10
Upside: -